[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541892":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":62,"collaborators":65,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":12,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":12,"overallStatus":46,"whyStopped":12,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Missouri-Columbia","OTHER",[8,13,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Lean Individuals","NO_INTERVENTION","No intervention will be administered.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Metabolically abnormal obese Individuals (obesity with normoglycemia and abnormal liver fat content)","EXPERIMENTAL","Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.",[18],"Other: Dietary consultation weight loss intervention",{"label":20,"type":15,"description":16,"interventionNames":21},"Metabolically normal obese Individuals (obesity with normoglycemia and normal liver fat content)",[18],{"label":23,"type":15,"description":16,"interventionNames":24},"Individuals with Type 2 Diabetes Mellitus",[18],[26],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":12},"Dietary consultation weight loss intervention","Participants will meet with a member of the study team biweekly for about 6 months.",[23,14,20],[31],{"name":32,"affiliation":5,"role":33},"Bettina Mittendorfer","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":12,"email":39},"Heather McHatton","CONTACT","(573) 882-7619","heathermchatton@health.missouri.edu",{"name":41,"role":37,"phone":12,"phoneExt":12,"email":42},"Aman Pritish Aher","amanpritishaher@umsystem.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of Missouri School of Medicine","RECRUITING","Columbia","Missouri","65212","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-92.33407,38.95171,{"lat":56,"lon":55},[59],{"name":32,"role":37,"phone":60,"phoneExt":12,"email":61},"573-882-9377","b.mittendorfer@missouri.edu",{"type":63,"investigatorFullName":32,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit",[66,69,71],{"name":67,"class":68},"National Institutes of Health (NIH)","NIH",{"name":70,"class":68},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"name":72,"class":6},"Washington University School of Medicine","100541892","harnessing-macrophage-lysosomal-lipid-metabolism-in-obesity-100541892",false,"NCT06335771","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases","ATM","Inclusion Criteria :\n\n* age: ≥18 but ≤70 years\n* not pregnant or breastfeeding\n* weight stable and sedentary before enrollment\n* no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \\[MAO\\]-Type 2 Diabetes group)\n* no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)\n* participants must fulfil all of the following group-specific inclusion criteria below:\n\nLean group:\n\n* Body mass index (BMI) ≥18.5 but \\\u003C25.0 kg\u002Fm2\n* Intrahepatic triglyceride (IHTG) content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* Hemoglobin A1C (HbA1c) \\\u003C5.7 %\n\nMetabolically normal obesity (MNO) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* HbA1c \\\u003C5.7 %\n\nMetabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\>7.5%\n* fasting blood glucose concentration: ≥100 but \\\u003C126 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \\\u003C200 mg\u002Fdl\n* HbA1c: ≥5.7 but \\\u003C6.4 %\n\nMAO-type 2 diabetes group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \\>126 mg\u002Fdl or blood glucose concentration 2 h after a 75 g oral glucose challenge\\>200 mg\u002Fdl or HbA1c \\>6.4 % without medication if not diagnosed and medically treated for diabetes\n\nExclusion Criteria:\n\n\\- Individuals that do not meet all inclusion Criterion",true,"ALL","18 Years","70 Years",{"count":86,"type":87},60,"ESTIMATED","INTERVENTIONAL",[90],"NA","The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.\n\nBoth groups will have:\n\n* screening visit\n* imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \\[MRI\\] and magnetic resonance spectroscopy \\[MRS\\] scans)\n* Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.",[93,94,95,96],"Obesity","Nonalcoholic Fatty Liver","Diabetes Type 2","Healthy","2025-07-16",{"date":99,"type":100},"2025-07-18","ACTUAL",{"date":102,"type":100},"2024-08-01",{"date":104,"type":87},"2028-03",{"name":32,"class":6},1]